
NOV Inc. is a global leader in designing, manufacturing, and marketing essential systems, components, and products for the oil and gas drilling and production industries, as well as for industrial and renewable energy sectors worldwide. The company's operations are divided into three core segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. The Wellbore Technologies segment provides a range of offerings including solids control and waste management equipment, portable power generation units, drill and wired pipes, advanced drilling optimization and…

Nov Inc. (NOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.

NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.

HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).